Clinical Trial

Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

Study acronym: CATCH-177
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out what treatment works best for participants with metastatic prostate cancer that are not responding to hormone treatment and docetaxel and are also Prostate-specific membrane antigen(PSMA) positive.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-12-12; most recent amendment 2025-08-26.
Status change: Not Yet Recruiting → Recruiting 2025-06-30
Trial Details
NCT Number NCT06738303
Lead Sponsor Case Comprehensive Cancer Center
Conditions Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Enrollment 44 participants
Start Date 2025-07-14
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-14